Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Hypoactive Sexual Desire Disorder (HSDD)

In brief

The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.

Key facts

Study ID

NCT03619005

Run by

EndoCeutics Inc.

People needed

0

Starts

2018-11-13

Expected to finish

2019-12-06

Last updated by the study team

2020-07-31

Who can join

Age: 40 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Endoceutics site # 106 — Huntsville, Alabama, United States
• Endoceutics site # 17 — San Diego, California, United States
• Endoceutics site # 125 — New London, Connecticut, United States
• Endoceutics site # 114 — St. Petersburg, Florida, United States
• Endoceutics site # 119 — Roswell, Georgia, United States
• Endoceutics site # 91 — Savannah, Georgia, United States
• Endoceutics site # 20 — New York, New York, United States
• Endoceutics site # 115 — Fargo, North Dakota, United States
• Endoceutics site # 127 — Bluffton, South Carolina, United States
• Endoceutics site # 102 — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.